12 Best Low Price Pharma Stocks To Invest In Right Now

4. Haleon plc (NYSE:HLN)

Share Price as of the Close of February 21: $10.08

Haleon plc (NYSE:HLN) is a British multinational consumer healthcare company specializing in OTC medications and wellness products. It operates across five categories: Oral Health, VMS, Pain Relief, Respiratory Health, and Digestive Health. The company generates revenue by marketing trusted brands directly to consumers and healthcare professionals through retail sales and pharmacy partnerships.

Haleon plc (NYSE:HLN) expects organic revenue growth of 4-6% for FY 2024, with operating profit growth in the high-single digits. The company’s £300 million productivity program is on track, reinvesting savings into advertising and clinical studies. However, divestitures of Lamisil, ChapStick, and NRT businesses outside the US will reduce revenue by 1.9% and adjusted operating profit by 5.2%.

Geographically, Q3 2024 showed strong growth in Asia Pacific (8.2%), followed by EMEA and LatAm (6.1%) and North America (4.8%). However, foreign exchange rates are expected to negatively impact revenue by 3.7% and adjusted operating profit by 6.5%. Haleon plc (NYSE:HLN) also completed the acquisition of a 33% equity stake in Tianjin TSKF in China, boosting future earnings by reducing Non-Controlling Interest.

Financially, the company’s Q3 organic revenue growth was 6.1%, driven by a 3.3% price increase and a 2.8% rise in volume/mix. Oral and Respiratory Health categories performed well, while Pain Relief declined due to tough comparatives in China but recovered in Q3. Haleon plc (NYSE:HLN) remains focused on long-term profitability through cost savings and reinvestments. The company completed its £500 million share buyback program and continues to manage its debt through bond repayments and new issuances.